Title : Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study - Rosenstock_2006_Clin.Ther_28_1556 |
Author(s) : Rosenstock J , Brazg R , Andryuk PJ , Lu K , Stein P |
Ref : Clin Ther , 28 :1556 , 2006 |
Abstract :
OBJECTIVE: The efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy were assessed in patients with type 2 diabetes and inadequate glycemic control (glycosylated hemoglobin [HbA(1c)] > or =7% and < or =10%) while receiving a stable dose of pioglitazone. |
PubMedSearch : Rosenstock_2006_Clin.Ther_28_1556 |
PubMedID: 17157112 |
Inhibitor | Sitagliptin |
Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
Clin Ther
28 :1556
Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P (2006)
Clin Ther
28 :1556